BACKGROUND: Population-based BRCA1/BRCA2 founder-mutation testing has been demonstrated as cost effective compared with family history based testing in Ashkenazi Jewish women. However, only 1 of the 3 Ashkenazi Jewish BRCA1/BRCA2 founder mutations (185delAG [c.68_69delAG]), 5382insC[c.5266dupC]), and 6174delT[c.5946delT]) is found in the Sephardi Jewish population (185delAG[c.68_69delAG]), and the overall prevalence of BRCA mutations in the Sephardi Jewish population is accordingly lower (0.7% compared with 2.5% in the Ashkenazi Jewish population). Cost-effectiveness analyses of BRCA testing have not previously been performed at these lower BRCA prevalence levels seen in the Sephardi Jewish population. Here we present a cost-effectiveness analysis for UK and US populations comparing population testing with clinical criteria/family historyebased testing in Sephardi Jewish women. STUDY DESIGN: A Markov model was built comparing the lifetime costs and effects of population-based BRCA1 testing, with testing using family historyebased clinical criteria in Sephardi Jewish women aged !30 years. BRCA1 carriers identified were offered magnetic resonance imaging/mammograms and risk-reducing surgery. Costs are reported at 2015 prices. Outcomes include breast cancer, ovarian cancer, and excess deaths from heart disease. All costs and outcomes are discounted at 3.5%. The time horizon is lifetime, and perspective is payer. The incremental cost-effectiveness ratio per quality-adjusted life-year was
G enetic testing for BRCA1/BRCA2 mutations has conventionally been offered to affected individuals or those fulfilling strict clinical or family history (FH)ebased criteria. However, using this FH-based approach results in greater than 50% of BRCA1/BRCA2 carriers being missed because they do not meet the threshold for these clinical criteria. 1, 2 The Genetic Cancer Prediction through Population Screening (GCaPPS) randomized trial (ISRCTN73338115) demonstrated population-based BRCA1/ BRCA2 founder mutation testing (performed regardless of personal or family history of cancer) in women of Ashkenazi Jewish (AJ) descent to be both cost saving and more effective compared with FH-based testing, 3 providing strong supporting evidence for its adoption.
UK and Israeli studies have shown that population-based BRCA1/BRCA2 testing in Ashkenazi Jews is feasible and acceptable and identifies more people at risk and does not cause detrimental psychological and quality-of-life consequences. 1, 2, 4 The increasing availability and access to next-generation-sequencing platforms and concomitant decreasing cost of genetic testing 5 has rendered largescale high throughput testing of populations both more affordable and technically feasible.
Given the findings of the GCaPPS randomized control trial and corroborating cohort studies, many have advocated for BRCA1/BRCA2 testing to be offered to the whole Jewish population, regardless of family history.
AJ are descendants of Jews who emigrated from France, Germany, and Eastern Europe in 1800s-1900s. Sephardi Jews (SJ) are descendants of Jews from Spain and Portugal (Sephardim) as well as North Africa, Iraq, and Morocco (Mizrachim). Approximately 25% of the Jewish population is not of Ashkenazi descent. 6 Importantly, while 3 BRCA1/ BRCA2 founder mutations (185delAG [c.68_69delAG], 5382insC[c.5266dupC], and 6174delT[c.5946delT]) have been described in AJ, only 1 of these (185delAG [c.68_69delAG]) is found in SJ. [7] [8] [9] Hence, the mutation prevalence is much lower in SJ (0.5%-1%) 8, 9 compared with AJ (2.5%). 2 Population-testing studies have been undertaken in the AJ population in the United Kingdom, Israel, and Canada and show acceptability of this approach as well as the feasibility of providing this outside a hospital setting. 2, 4, 10 While evidence exists to support a shift toward population-based testing in the AJ community, this evidence cannot be used to reach the same conclusion for the whole Jewish community because corresponding data on cost-effectiveness are lacking for the Sephardi population with the lower prevalence of mutations. This highlights the need for a greater evidence base in the SJ population.
A cost-effectiveness assessment is a vital tool used to evaluate the costs and benefits of different health interventions. This helps with the allocation of scarce resources within health care and assists with policy decision making. 11 In this study we for the first time evaluate and report on the cost-effectiveness of population-based BRCA testing in the SJ population.
Materials and Methods
The lifetime costs and effects of BRCA1 testing were analyzed through a Markov model (Figure 1 ) comparing the current practice of clinical criteria/FH testing to population testing of all SJ women aged !30 years for the BRCA1 SJ mutation. Separate analyses were performed for UK and US populations.
Other analytical models assume all events occur simultaneously in the same time sequence. However, with a disease such as cancer, events are likely to occur over a period of time. A Markov model allows for this temporal element and permits patients to move through mutually exclusive health states through a series of transition probabilities over a period of time.
The Markov model assumes genetic counseling and genetic testing were undertaken in women fulfilling clinical testing criteria in the FH arm and in all women in the population-testing arm. Clinical criteria for testing includes the following: personal history of ovarian cancer (OC) at any age; first-degree relative with OC (any age); first-degree relative with or personal history of breast cancer (BC) aged <50 years; or first-degree relative with or personal history of male breast cancer at any age. 2 Testing positive for the BRCA1 mutation resulted in women being offered a risk-reducing salpingo-oophorectomy (RRSO), which would lead to a reduction in their OC risk. 12 To reduce their BC risk, women testing positive were offered magnetic resonance imaging (MRI) and mammography screening or a risk-reducing mastectomy (RRM). 13 Premenopausal bilateral oophorectomy is associated with an increased risk in cardiovascular mortality, especially in women who do not take hormone replacement therapy (HRT). 14, 15 The increased cardiovascular risk (number needed to harm ¼ 1:33) is integrated in the model, and HRT is given to women until the age of 51 years (menopause) if they have an RRSO, with HRT compliance assumed to be 80% (confidence interval, 76e83%). 16 Additionally, costs of bone health monitoring and HRT supplementation are included in the model. All costs and outcomes were discounted at a rate of 3.5% in line with the reference case guidelines published by the National Institute of Health and Care Excellence (NICE).
17 BC risk is not affected by taking short-term HRT after RRSO. 18 Because a mortality benefit has not been shown with OC screening, it has been excluded from the model. 18 
Probabilities
The various probabilities used in the model are described in Table 1 .
Costs
Costs are reported at 2015 prices and where required have been converted using the Hospital and Community Health Service Index. 19, 20 They are derived from the health system/payer perspectives. These are described in detail in Table 2 . In line with the NICE recommendations, future health care costs outside those associated with OC/BC were not considered.
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Life-years
Lifetime horizons extending to 83/82 years for the female UK/US populations were used to model the lifetime risks and consequences of BRCA testing. General population life tables were obtained from the Office of National Statistics for the UK population and from Surveillance, Epidemiology, and End Results Program for the US population. Specific SJ data are unavailable for these estimates. Hence, lifetime SJ risks and survival estimates are assumed to be the same as the rest of the general population.
The mean age for BC/OC onset was 41/ 54 years for BRCA1 mutations in SJ women, respectively.
21, 22 The mean ages for sporadic BC and OC were 57/62 years and 63/63 years in the UK/US populations, respectively. [22] [23] [24] Probability of dying from background mortality was taken from the general UK and US populations in the absence of SJ distinct data. 25 Statistically significant differences in survival have not been observed between BRCA1 genetic and sporadic BC cases. [26] [27] [28] No statistically significant difference in 10 year survival rates have been found between BRCA1 OC and sporadic OC either. 29 The average 10 year survival for BC is 78.4%/84.6% and OC is 34.5%/34.2% in UK/US populations. 29, 30 After 10 years of survival, the probability of death was assumed to be the same as the general population.
Quality-adjusted life-years (QALY)
QALYs are a measure of health outcomes recommended by NICE for use in economic evaluations. It uses utility weights, which reflects the preference of an individual for a particular health state between 1, indicating perfect health, and 0, indicating death. Utility weights are multiplied by survival in life-years to produce the QALY measure. 31 The following utility scores were used for early, advanced, recurrent, and end stages of BC: 0.71, 0.65, 0.45, and 0.16, respectively, and were obtained from NICE guidance. 32 The following utility scores were used for early, advanced, recurrent, and end stages of OC: 0.81, 0.55, 0.61, and 0.16, respectively. 33 In addition, women may experience negative health effects from undertaking an RRM and RRSO. 34, 35 To account for this, utility scores of 0.88 (SD, 0.22) for RRM and 0.95 (SD, 0.10) for RRSO were incorporated in the model. 36 
Analysis
The Markov model used to evaluate the costs and outcomes is illustrated in 
Markov model structure
Schematic diagram showing the Markov model structure for population and clinical criteria/FHebased testing for BRCA mutations. In the population testing arm, all SJ women !30 years old are offered BRCA1 founder mutation testing. If SJ women test BRCA1 positive, they are then offered an RRM and RRSO. Depending on the probability of women undertaking an RRM and/or RRSO they are placed into different health states and then progress to either BRCA1-associated BC or OC. In the FH arm, only women who have positive FH criteria matching the current guidelines on genetic testing are offered a genetic test. They then follow the same pathway as women in the population testing. Women with a negative FH are either BRCA1 negative or have an undetected BRCA1 mutation. BRCA1-negative women progress to sporadic non-BRCA OC or non-BRCA BC. Undetected BRCA1 SJ women progress to BRCA1-associated BC or BRCA1-associated OC. All women undergoing an RRSO have an increased risk of fatal CHD. Although not shown in the figure, background mortality has been modeled for all health states. Progression through the model is dependent on the probabilities presented in Table 1 .
BC, breast cancer; CHD, coronary heart disease; FH, family history; OC, ovarian cancer; RRM, risk-reducing mastectomy; RRSO, risk-reducing salpingo-oophorectomy; SJ, Sephardi Jewish. The costs of the population-testing arm were compared with the costs of the FHbased testing arm. The effects evaluated in both arms were evaluated in terms of total life-years and QALYs. The discount rate of 3.5% was used for both costs and effects, in line with the NICE reference case, which acknowledges values for future costs, and benefits are considered lower in value than in the present.
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The incremental cost-effectiveness ratio (ICER) was estimated by dividing the difference in cost between the 2 P1 indicates the probability of carrying a BRCA founder mutation in an unselected SJ population is calculated from an analysis carried out by Bar-Sade et al 8 ; the estimate was calculated by dividing the number of 185delAG BRCA1 mutations detected in the Iraqi and Moroccan Jews by the total number of samples taken from those 2 countries (7/993). P2 indicates the probability of RRM uptake for a BRCA1 carrier is taken from Evans et al 57 (2009) . P3 indicates the reduction in ovarian cancer risk in BRCA1 carriers is obtained from Kauff et al 54 (2008) , whose findings are consistent with other studies reporting that following an RRSO, a 4% risk of peritoneal cancer remains. P4 indicates the probability that a BRCA1 carrier without RRSO will get ovarian cancer is taken from Chen et al 12 (2007) . P5 indicates estimates for a risk of ovarian cancer in non-BRCA UK carriers is obtained from Cancer Research UK 58 and from SEER data 24 for US carriers. P6 indicates that the GCaPPS study provides the estimates for the probability of having a positive family history, fulfilling current clinical criteria for genetic testing in a Jewish population.
3 P7 indicates BRCA1 mutation prevalence in FH-positive individuals is obtained from Bar-Sade et al, 1998 8 : 6 carriers detected in 112 Sephardi individuals with breast or ovarian cases, giving a probability of 0.053 (6/112). P8 indicates BRCA1 prevalence in family historyenegative individuals is obtained by multiplying the probability of having a strong FH, fulfilling current clinical criteria for genetic testing (P6) by the BRCA1 mutation prevalence in FH-positive individuals (P7); this value was then taken away from the BRCA1 mutation prevalence in general population controls (P1) to get the BRCA1 mutation prevalence in FH-negative individuals (P8): 0.007049 e (0.123 * 0.053). P9 indicates a reduction in breast cancer risk from RRM in BRCA1 carriers is obtained from Prevention and Observation of Surgical End Points (PROSE) study data reported by Rebbeck et al 13 (2004) . P10 indicates the probability that a BRCA1 carrier without RRM will get breast cancer is obtained from a meta-analysis conducted by Chen et al 12 (2007) . P11 indicates the estimates for the risk of breast cancer in UK non-BRCA carriers is taken from the UK Office for National Statistics and from Cancer Research UK 58 and from SEER data 24 for US women. P12 indicates the probability of a BRCA1 carrier undergoing an RRSO are taken from Evans et al 57 (2009) . P13 indicates that a reduction in the risk of breast cancer from RRSO alone in a BRCA1 carrier is obtained from a meta-analysis by Rebbeck et al 59 (2009) . P14 indicates that a reduction in the risk of breast cancer in BRCA1 carriers undergoing an RRM and RRSO is obtained from data from the PROSE study by Rebbeck et al 13 (2004) . P15 indicates that the risk of mortality from CHD after RRSO is taken from the Nurses Health Study 14 ; this is reported as 0.0303 premenopausal women not taking HRT but undergoing a RRSO. P16 indicates that the compliance rate for HRT is taken from Read et al 16 (2010) and the lower limit of the range modeled is from Garcia et al 60 (2015) . 62 until the average age of menopause at 51 years with an 80% compliance rate assumed. Bone health monitoring and osteoprotection costs are comprised of 3 follow-up dual-energy X-ray absorptiometry scans and daily calcium and vitamin D3 supplementation for osteoprotection. 19 Prophylactic salpingo-oophorectomy costs in the US population are taken from Grann et al 36 (2011) and inflated to 2015 prices using the medical component of the US consumer price index. For ovarian cancer costs, diagnosis costs include a pelvic examination, ultrasound, percutaneous biopsy and cytology, a computed tomography scan, and a CA125 test. Treatment costs include surgical costs for a lower and upper genital tract procedure with 6 chemotherapy cycles of carboplatin and paclitaxel and chemotherapy administration costs. Follow-up costs include consultant visits, a computed tomography scan, and CA125 tests and recurrent ovarian cancer treatment costs. 19 ,64 UK costs are taken from NICE guideline and NHS reference costs. 19, 64 Ovarian cancer costs for the US population are taken from Grann et al 36 (2011) and inflated to 2015 prices using the medical component of the US consumer price index. Breast cancer screening for non-BRCA carriers follows the UK NHS breast cancer screening program in which mammography is offered every 3 years from the age of 50 years until 70 years. 72 For the United States, recommendations in a Centers for Disease Control and Prevention report were followed whereby mammography is offered every 2 years from the age of 50 years until 70 years. 73 Breast cancer screening for BRCA1 carriers follows NICE guideline on familial breast cancer in which an annual magnetic resonance imaging scan is offered from the age of 30 years to 49 years. An annual mammogram is offered from the age of 40 years to 69 years. 69 For the United States, recommendations in a Centers for Disease Control and Prevention report were followed whereby a magnetic resonance imaging scan and mammography are offered annually from the age of 30 years until 50 years. Mammography is then offered annually from the age of 50 years until 70 years. 73 UK costs are obtained from NHS reference costs. 19 US costs of mammography and magnetic resonance imaging are taken from Grann et al 36 (2011) and inflated to 2015 prices using the medical component of the US consumer price index. RRM costs are weighted for a 21% complication rate 67, 74 and obtained from NHS reference costs. 19 The cost of RRM is taken from Grann et al 36 (2011) and inflated to 2015 prices using the medical component of the US consumer price index. Breast cancer treatment costs include mammogram, ultrasound, clinical examination biopsy, 70 and sentinel lymph node biopsy and axillary lymph node dissection. 75 Differences in non-BRCA and BRCA cancer treatment costs arise from the proportion of cancers that are noninvasive DCIS and invasive. In non-BRCA populations, 10% of breast cancer is noninvasive DCIS and 90% breast cancer is invasive. [75] [76] [77] [78] In BRCA populations, 20% of cancers are DCIS and 80% are invasive.
67, 79 Costs include costs of breast-conserving surgery, radiotherapy, 70 chemotherapy, endocrine therapy, 32,70 and bisphosphonate costs 62 and trastuzumab costs for HER2-positive breast cancer.
75 Follow-up costs and treatment of relapse/recurrence are included. [80] [81] [82] The cost of breast cancer treatment is taken from Grann et al 36 (2011) and inflated to 2015 prices using the medical component of the US consumer price index. For terminal cancer costs, the end-of-life care costs for breast and ovarian cancer are obtained from the end-of-life care report submitted to the National Audit Office, United Kingdom, 66 and from Grann et al 36 39, 40 to assess the cost-effectiveness of populationbased BRCA1 founder-mutation testing in SJ women.
The baseline ICER calculated includes the benefit in BC-risk reduction from undergoing an RRSO. However, this benefit has recently been questioned by a Dutch group. 41 Therefore, scenario analyses were performed for comparing population testing with FH testing in which no reduction in BC risk occurred following RRSO. A further scenario explored the impact on the results in which no HRT was offered. Additionally, because RRM and RRSO rates in Israeli Jews are reported to be lower than BRCA carriers living in Europe/North America, a scenario analysis of lower RRM rate (13%) and lower RRSO rate (49%) was also evaluated. 42 The parameters used in the model have a certain degree of uncertainty associated with them. To explore the uncertainty of the model results, an extensive sensitivity analysis was undertaken. One-way sensitivity analysis varies the estimate of 1 parameter at a time, keeping all other parameters at their baseline to assess the impact of that parameter on the ICER. Probabilities and utility scores were varied by their 95% confidence intervals, whereas costs were altered by AE30%.
One-way analysis provides information on which parameter has the largest impact on the ICER and therefore highlights parameters of major significance, which could be the focus of further research. However, parameters are most likely to vary together and not independently of each other, so probabilistic sensitivity analysis (PSA) was also conducted.
In the PSA, parameters were varied simultaneously according to their distributions for a total of 10,000 iterations to investigate joint uncertainty. Distributions were assigned according to the literature: probabilities and utilities were fitted with a beta distribution and costs with gamma distributions. 43, 44 The results of the 10,000 iterations were plotted on a cost-effectiveness acceptability curve, which portrays the proportion of simulations that are cost effective at differing WTP thresholds for each arm of the Markov model.
Results
The discounted values for total cost, QALYs, and life-years for both the population-based testing and the clinical criteria/FHebased testing approaches are given in Table 3 . The results show population testing in SJ is cost effective compared with the current practice of BRCA testing using FH-based clinical 
FIGURE 2
One-way sensitivity analysis for top 6 parameters affecting UK ICER
One-way sensitivity analysis in the form of a tornado diagram for the top 6 parameters that have the largest impact on the ICER of population-based testing for BRCA1 founder mutations, compared with an FH-based approach in the United Kingdom. On the Y-axis, the top 6 parameters with the greatest impact on ICER are shown. On the X-axis, ICER per QALY (discounted) calculated through varying probabilities and utilities by its upper and lower 95% confidence intervals or range as described in Table 1 are shown. Costs were varied by AE30%. The minimum value represents the lower limit of the parameter, and the maximum value represents the upper limit of the parameter. . This is significantly below the NICE threshold of £20,000/QALY and $100,000/QALY US WTP threshold, indicating population testing is highly cost effective. One-way sensitivity analysis was undertaken for all the probabilities, costs, and utilities. Figures 2 and 3 show the parameters that had the largest impact on the ICER in the UK and US 1-way analysis, respectively. The model was most sensitive overall to BRCA1 mutation prevalence estimates in the Sephardi population and in FH-positive individuals. However, these results still remain cost effective at very well below the £20,000e30,000/QALY and $100,000/QALY WTP thresholds. The PSA (Figures 4 and 5) shows that 100% of the iterations are cost effective for population-based testing at the £20,000/QALY and $100,000/QALY WTP thresholds, again reconfirming that this strategy is highly cost effective.
The model remains cost effective for the various scenario analyses undertaken. If it is assumed there is no risk reduction in BC risk following RRSO, then the ICER becomes £67.69/ QALY with 12.18 months gain in life expectancy in the United Kingdom and an ICER of $311.25/QALY with 12.17 months gain in life expectancy in the United States.
If women decline or are unable to take HRT, then the ICER for population testing increases to £67.05/QALY and $308.48/QALY, with a gain in life expectancy of 12.18/12.17 months in the United Kingdom/United States, respectively. The model is not very sensitive to the parameter of HRT use, and the PSA shows that at >99% simulations remain cost effective at lower rates of use.
A lower uptake of RRM at 13% and RRSO at 49% has been reported in the Jewish population. 42 Assuming a lower uptake of both surgeries, the ICER increases to £67.81/QALY and $312.84/ QALY in United Kingdom/United States populations with 12.17 months' gain in life expectancy in both populations. All three scenarios represent a slight increase from the baseline ICERs of £67.04 and $308.42 in the United Kingdom and United States populations. However, all scenarios remain cost effective and markedly below the NICE £20,000/ QALY and US $100,000/QALY WTP thresholds. In addition, even if the cost of testing rises to $2000/test population, testing remains cost effective, with an ICER of $1798/QALY.
Comment
Population-based BRCA testing in the SJ population is highly cost effective compared with a clinical criteria/FHe based strategy with an ICER of £67.04/ QALYand $308.42/QALY, well below the NICE £20,000e30,000/QALY and US $100,000/QALY WTP thresholds, respectively. That 100% of simulations are cost effective (£20,000/QALY and $100,000/QALY WTP thresholds), despite uncertainty in model parameters, is highly reassuring.
Whereas evidence exists on the costeffectiveness of population testing in other Jewish populations, notably the AJ population, 3 the literature has been lacking for the SJ population. This report addresses this knowledge gap and finds population testing for BRCA1 founder mutations in SJ women to also be highly cost effective, resulting in 12 months of estimated life expectancy gained over clinical criteriaedriven testing. Approximately 20% of the Jewish population is Sephardi. 6 These findings coupled with our earlier analysis showing cost-effectiveness in the AJ population 3, 45 support populationbased BRCA testing in the entire Jewish population.
This study has a number of advantages. The comparator used in this analysis is based on current practice and NICE/published clinical guidelines for BRCA management. In addition, the analysis meets NICE guidelines on economic evaluations. QALYs have been used as the measure of health effects, and costs and outcomes are discounted at the recommended 3.5% rate. The lifetime time horizon used is advantageous in mapping the full costs and outcomes over the lifetime of female SJ and not just the costs and outcomes occurred at the point of intervention. Furthermore, the possible adverse effects of undertaking prophylactic RRM and/or RRSO are One-way sensitivity analysis for top 6 parameters affecting US ICER One-way sensitivity analysis in the form of a tornado diagram for the top 6 parameters that have the largest impact on the ICER of the population-based testing for BRCA1 founder mutations, compared with an FH-based approach in the United States. On the Y-axis, the top 6 parameters with the greatest impact on ICER are shown. On the X-axis, ICER per QALY (discounted) calculated through varying probabilities and utilities by its upper and lower 95% confidence interval or range as described in Table 1 . Costs were varied by AE30%. The minimum value represents the lower limit of the parameter, and the maximum value represents the upper limit of the parameter. We also include a detriment for cardiovascular mortality associated with HRT noncompliance. Incorporating these effects limits overestimating the number of QALYs acquired through surgical prevention, which in turn minimizes underestimating the final baseline ICER/QALY. The 1-way sensitivity and PSA show that the model is robust to the various parameter estimates. The confidence intervals or range of these estimates are reasonably wide. Costs of surgical prevention or treatment costs for OC, BC, or cardiovascular events do not have a significant impact on the model results.
There are also limitations of this model. As far as possible, populationbased data have been used to obtain the parameters in the analysis. However, primary data for the BRCA mutation prevalence in FH-negative SJ women are unavailable, and this has been calculated by using a combination of other parameters, such as the overall BRCA mutation prevalence in SJ women, BRCA mutation prevalence in FH-positive individuals, and the probability of having a positive FH, fulfilling the genetic testing criteria (Table 1) . But the 3 probabilities used to calculate this value have been determined from population-based data, and the value used in the analysis (0.000493) is realistic and similar to estimates expected from a low-risk general population. 46 Additionally, the sensitivity analysis has found population testing to still be cost effective despite the significant uncertainty around this parameter. We have not included the benefit of tamoxifen-based chemoprevention reported in high-risk women. Tamoxifen prevents mainly estrogen receptorepositive BC, and w70% of BRCA1-associated BC are estrogen receptor negative. 47, 48 In addition, overall uptake rates reported in the literature are low (w16%) 49 and unknown for the SJ population. Including tamoxifen would make the model more cost effective, and we chose not to overestimate its benefit, given that tamoxifen has not been shown to reduce the incidence of estrogen receptorenegative BC.
Our analysis covers testing for the BRCA1 founder mutation, which is common in SJ. Women with a very strong FH of cancer (similar to that found in the non-Jewish general population) who test negative for the SJ founder mutation should be referred to clinical genetics for a full/extended BRCA1/BRCA2 screen analysis for nonfounder mutations.
The different scenarios tested by the model add to the strength of the analyses. The risk of coronary heart disease (CHD) from undertaking an RRSO has been incorporated into the model, assuming an 80% HRT compliance, yet the true compliance rate in a SJ population has not been fully determined. This is important because HRT alleviates cardiovascular risk, and the cardiovascular mortality impact is seen predominantly in those who are noncompliant. 14 However, HRT compliance does not seem to have a major impact on the overall results because population testing remains highly cost effective, even at the 0% compliance rate in our scenario analysis.
Our analysis does not include the excess mortality caused by lung/colorectal cancer reported in the Nurses Health Study because it may be confounded by cigarette smoking or other risk-related behaviors, and this finding has not been corroborated in some other larger studies. Smoking itself is associated with early menopause. 50, 51 Additionally, results of the National Institutes of HealtheAmerican Association of Retired Persons Diet and Health Study in 185,017 women found stratification by smoking status, demonstrated that increased lung cancer risk associated with bilateral oophorectomy was absent in nonsmokers, and was restricted only to smokers. 50 In addition, the European Prospective Investigation into Cancer and Nutrition (EPIC) study results (337,802 women) found no significant association between colorectal cancer risk and age at menarche/menopause or type of menopause (surgical/natural). 52 Nevertheless, we modeled a scenario of increased all-cause mortality (number needed to harm of 1 in 8) reported by Parker et al 14 and found that population testing in SJ remains cost effective (ICER ¼ £67/ QALY or $308/QALY).
Whether premenopausal oophorectomy leads to a reduction in BC risk has recently been the subject of recent debate. Although a recent Dutch paper found no such benefit, 41 other investigators have reported a BC-risk reduction with premenopausal oophorectomy. [53] [54] [55] Given the recent uncertainty around this parameter, if we assume no benefit from premenopausal oophorectomy, then the ICER increases, but the value is still well below the NICE and US WTP thresholds, indicating that population-based testing is still cost effective.
Specific uptake rates of RRM and RRSO in SJ women are lacking. In the absence of these data, we used RRM and RRSO rate data from UK BRCA1 carriers. It is reassuring that population testing remains cost effective, even at lower uptake rates of 13% for RRM and 49% for RRSO (ICER ¼ £67.81/QALY and $312.84/QALY) reported in Israeli women compared with women from Western populations. 42 The Jewish population is the first population in whom unselected population-based BRCA testing has been extensively evaluated and can become a reality. Overall, this does not harm psychological well-being or quality of life. 2 Our study shows population testing for BRCA1 mutations in SJ is extremely cost effective compared with traditional FH-based testing and supports a paradigm change to population-based testing in the SJ population.
This corroborates initial results from the AJ population, 3, 45 providing the rationale for offering BRCA foundermutation testing in the entire Jewish population. This could have implications for BRCA testing in other founder populations also. The number of cases of BC and OC are expected to increase by 24% and 27% in the United Kingdom, by 34% and 39% in the United States, by 51% and 55% in Israel and by 55% and 55% worldwide by 2035. 56 Identification of high-risk individuals who can benefit from effective preventive interventions provides an excellent opportunity to reduce the burden of BC and OC. It is extremely important that we utilize this opportunity offered by a population-testing strategy for maximizing cancer prevention. Delivering such a strategy will warrant broadening of existing and development of new referral and management pathways. These will differ from one country to another.
There is also the need to increase public and health professional awareness and knowledge as well as develop closer coordination and better communication between general practitioners, hospital health professionals, stakeholder and professional organizations, community charities, and the public at large. n
